Skip to main content
Signal8

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival

$INCYPress releaseJun 13, 2026, 6:00 AM ETRead the release

Incyte reported positive pivotal Phase 3 frontMIND trial results for tafasitamab (Monjuvi/Minjuvi) plus lenalidomide and R-CHOP in previously untreated high-risk DLBCL and HGBL. The combination significantly prolonged progression-free survival, reducing the risk of disease progression or death by 25% (HR 0.75, p=0.0194) compared to R-CHOP alone, with benefits observed across key molecular subgroups.

Key figures

Drug Name
Tafasitamab (Monjuvi/Minjuvi)
Phase Of Trial
Phase 3
Os hazard ratio
0.85
Pfs 2yr control
62.9%
Pfs 3yr control
60.7%
Efs hazard ratio
0.79
Enrollment count
899
Pfs hazard ratio
0.75
Pfs 2yr treatment
71.1%
Pfs 3yr treatment
67.3%
Pfs risk reduction
25%
Mrd negativity control
66.7%
Median follow up months
35.2
Mrd negativity treatment
81.3%

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.